Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma

BACKGROUND: A new predictive biomarker for determining prognosis in patients with hepatocellular carcinoma (HCC) who receive sorafenib is required, because achieving a reduction in tumor size with sorafenib is rare, even in patients who have a favorable prognosis. Vascular endothelial growth factor...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsuchiya, Kaoru, Asahina, Yasuhiro, Matsuda, Shuya, Muraoka, Masaru, Nakata, Toru, Suzuki, Yuichiro, Tamaki, Nobuharu, Yasui, Yutaka, Suzuki, Shoko, Hosokawa, Takanori, Nishimura, Takashi, Ueda, Ken, Kuzuya, Teiji, Nakanishi, Hiroyuki, Itakura, Jun, Takahashi, Yuka, Kurosaki, Masayuki, Enomoto, Nobuyuki, Izumi, Namiki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4209122/
https://www.ncbi.nlm.nih.gov/pubmed/24122122
http://dx.doi.org/10.1002/cncr.28384

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4209122/
https://www.ncbi.nlm.nih.gov/pubmed/24122122
http://dx.doi.org/10.1002/cncr.28384

Ejemplares similares